NTLA Q3 2024 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-24.0% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$145M-1589.0% margin

Net Income

-$136M-1489.5% margin

EPS (Diluted)

$-1.34

QoQ Revenue Growth

+31.0%

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$86M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$211M

Stockholders' Equity

$963M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$12M	-24.0%
Gross Profit	$9M	$10M	-6.1%
Operating Income	-$145M	-$131M	-10.4%
Net Income	-$136M	-$122M	-11.0%